Continuation of TTFields after recurrence in patients with glioblastoma may be associated with prolonged post-recurrence survival

Purpose The efficacy of tumor-treating fields (TTFields) in newly diagnosed glioblastoma is established, but the benefit of continuing treatment after first recurrence remains unclear. This study evaluated the association between TTFields continuation and survival after recurrence. Methods This single-center retrospective cohort study included consecutive patients with newly diagnosed supratentorial glioblastoma who received TTFields between April 2018 and December 2025. TTFields were initiated with maintenance temozolomide after standard chemoradiation. At first radiographic progression, patients chose whether to continue or discontinue TTFields. Post-recurrence survival and overall survival from surgery were analyzed using the Kaplan–Meier method and Cox proportional hazards models. TTFields adherence (≥ 75% vs. <75%) was also evaluated. Results Of 39 TTFields-treated patients, three without recurrence and one with missing usage data were excluded, leaving 35 for analysis: 15 continued treatment after recurrence and 20 discontinued it. Baseline characteristics did not differ significantly between groups. Overall survival from surgery did not differ significantly (median, 35 vs. 20 months; p = 0.104), whereas post-recurrence survival was longer in the continuation group (median, 11 vs. 9 months; p = 0.0434). Survival did not differ significantly by adherence (≥ 75% vs. <75%). In multivariable Cox proportional hazards analysis adjusted for age, sex, and adherence, continued TTFields use remained associated with longer post-recurrence survival (adjusted hazard ratio, 0.376; 95% confidence interval, 0.150–0.943; p = 0.0370). Conclusion Continuing TTFields after first recurrence was associated with longer post-recurrence survival. This association persisted after adjustment for age, sex, and adherence, although the retrospective design and small sample size limit causal interpretation.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11464407/v1
Primary Topic
Glioma Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Continuation of TTFields after recurrence in patients with glioblastoma may be associated with prolonged post-recurrence survival

Hiroyuki Ikeda, Shigeki Takada, Masahiro Tanji, Shinya Tokunaga et al.
5 links
Research Square
Glioma Diagnosis and Treatment
preprint

Continuation of TTFields after recurrence in patients with glioblastoma may be associated with prolonged post-recurrence survival

Hiroyuki Ikeda, Shigeki Takada, Masahiro Tanji, Shinya Tokunaga, Noritaka Sano, Takeshi Miyata, Yoshiki Arakawa, Yohei Mineharu, Etsuko Hattori-Yamamoto
preprint en

Abstract

Purpose The efficacy of tumor-treating fields (TTFields) in newly diagnosed glioblastoma is established, but the benefit of continuing treatment after first recurrence remains unclear. This study evaluated the association between TTFields continuation and survival after recurrence. Methods This single-center retrospective cohort study included consecutive patients with newly diagnosed supratentorial glioblastoma who received TTFields between April 2018 and December 2025. TTFields were initiated with maintenance temozolomide after standard chemoradiation. At first radiographic progression, patients chose whether to continue or discontinue TTFields. Post-recurrence survival and overall survival from surgery were analyzed using the Kaplan–Meier method and Cox proportional hazards models. TTFields adherence (≥ 75% vs. <75%) was also evaluated. Results Of 39 TTFields-treated patients, three without recurrence and one with missing usage data were excluded, leaving 35 for analysis: 15 continued treatment after recurrence and 20 discontinued it. Baseline characteristics did not differ significantly between groups. Overall survival from surgery did not differ significantly (median, 35 vs. 20 months; p = 0.104), whereas post-recurrence survival was longer in the continuation group (median, 11 vs. 9 months; p = 0.0434). Survival did not differ significantly by adherence (≥ 75% vs. <75%). In multivariable Cox proportional hazards analysis adjusted for age, sex, and adherence, continued TTFields use remained associated with longer post-recurrence survival (adjusted hazard ratio, 0.376; 95% confidence interval, 0.150–0.943; p = 0.0370). Conclusion Continuing TTFields after first recurrence was associated with longer post-recurrence survival. This association persisted after adjustment for age, sex, and adherence, although the retrospective design and small sample size limit causal interpretation.

Research Square
Kyoto University (JP)
Japan Agency for Medical Research and Development
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon